Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04770246 · ClinicalTrials.gov registry record · Phase 1
TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations
A Phase 1 study, sponsored by Taiho Oncology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT04770246 is a Phase 1 study that was terminated before completion, run by Taiho Oncology. The registered enrollment target is 17 participants.
The verdict
NCT04770246, a Phase 1 study, was terminated before completion, sponsored by Taiho Oncology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of TAS-117 in patients with advanced or metastatic solid tumors (excluding primary brain tumors) harboring germline PTEN inactivating mutations.
Interventions
- DRUG TAS-117
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2021-03-31 |
| Est. Completion | 2023-03-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04770246
The ClinicalTrials.gov registry entry for NCT04770246 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taiho Oncology, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAS-117 is the first listed.
NCT04770246 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04770246 about?
NCT04770246 is a clinical study titled "TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of TAS-117 in patients with advanced or metastatic solid tumors (excluding primary brain tumors) harboring germline PTEN inactivating mutations.
What is the current status of trial NCT04770246?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2021-03-31. Estimated completion is 2023-03-06.
What interventions are being tested in trial NCT04770246?
The interventions under investigation include: TAS-117 (DRUG).
Who is sponsoring clinical trial NCT04770246?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.